HomeAI · summaries
Storia in 4 fonti
AbCellera stock surges on ABCL635 menopause Phase 2 trial results
A single dose of ABCL635 cut hot flash frequency by 83% after four weeks, compared with 33% for placebo
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and…
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a…
- ·
endpoints.news
AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
AbCellera's $ABCL surged 38% after ABCL635 cut hot flash frequency 50% over placebo in Phase 2, outperforming Astellas' Veozah and Bayer's Lynkuet.
